U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H20Br2N2O3
Molecular Weight 484.182
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of JNJ-10397049

SMILES

CC1(C)OC[C@H](NC(=O)NC2=CC=C(Br)C=C2Br)[C@@H](O1)C3=CC=CC=C3

InChI

InChIKey=RBKIJGLHFFQHBE-IRXDYDNUSA-N
InChI=1S/C19H20Br2N2O3/c1-19(2)25-11-16(17(26-19)12-6-4-3-5-7-12)23-18(24)22-15-9-8-13(20)10-14(15)21/h3-10,16-17H,11H2,1-2H3,(H2,22,23,24)/t16-,17-/m0/s1

HIDE SMILES / InChI

Molecular Formula C19H20Br2N2O3
Molecular Weight 484.182
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21181123 | https://www.ncbi.nlm.nih.gov/pubmed/17638707 | https://www.ncbi.nlm.nih.gov/pubmed/24592208 | https://www.ncbi.nlm.nih.gov/pubmed/19363060 | https://www.ncbi.nlm.nih.gov/pubmed/17638707

JNJ-10397049 is a potent and selective antagonist of the orexin-2 receptor. JNJ-10397049 regulated ovulation, and sleep promotion. JNJ-10397049 was reported to be effective in reducing the reinforcing effects of ethanol.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.3 null [pKi]
5.18 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Both orexin receptors are expressed in rat ovaries and fluctuate with the estrous cycle: effects of orexin receptor antagonists on gonadotropins and ovulation.
2007 Oct
Functional and binding kinetic studies make a distinction between OX1 and OX2 orexin receptor antagonists.
2012 Oct 5
Patents

Sample Use Guides

JNJ-10397049 (1, 3, and 10 mg/kg, sc) dose-dependently reduced ethanol self-administration without changing saccharin self-administration, dopamine levels, or withdrawal signs in rats. Treatment with JNJ-10397049 (10 mg/kg, sc) attenuated the acquisition, expression, and reinstatement of ethanol conditioned place preference and ethanol-induced hyperactivity in mice.
Route of Administration: Other
In Vitro Use Guide
Curator's Comment: Both orexin A and orexin B increased FSH and LH secretion in vitro in anterior pituitary cells of proestrous rats; these effects was suppressed by the orexin 2 receptor antagonist JNJ-1039704
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:36:14 UTC 2023
Edited
by admin
on Sat Dec 16 08:36:14 UTC 2023
Record UNII
1B419P24AV
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
JNJ-10397049
Common Name English
UREA, N-(2,4-DIBROMOPHENYL)-N'-((4S,5S)-2,2-DIMETHYL-4-PHENYL-1,3-DIOXAN-5-YL)-
Systematic Name English
1-(2,4-DIBROMOPHENYL)-3-((4S,5S)-2,2-DIMETHYL-4-PHENYL-(1,3)DIOXAN-5-YL)UREA
Systematic Name English
Code System Code Type Description
CAS
708275-58-5
Created by admin on Sat Dec 16 08:36:14 UTC 2023 , Edited by admin on Sat Dec 16 08:36:14 UTC 2023
PRIMARY
EPA CompTox
DTXSID501336831
Created by admin on Sat Dec 16 08:36:14 UTC 2023 , Edited by admin on Sat Dec 16 08:36:14 UTC 2023
PRIMARY
WIKIPEDIA
JNJ-10397049
Created by admin on Sat Dec 16 08:36:14 UTC 2023 , Edited by admin on Sat Dec 16 08:36:14 UTC 2023
PRIMARY
FDA UNII
1B419P24AV
Created by admin on Sat Dec 16 08:36:14 UTC 2023 , Edited by admin on Sat Dec 16 08:36:14 UTC 2023
PRIMARY
PUBCHEM
9869934
Created by admin on Sat Dec 16 08:36:14 UTC 2023 , Edited by admin on Sat Dec 16 08:36:14 UTC 2023
PRIMARY
Related Record Type Details
ACTIVE MOIETY